Live Blog

MARKET WRAP: Sensex up 95 pts; PSBs rally; Bajaj Auto up 1% post Q2 results

Sectorally, Nifty Auto and PSU Bank indices ended the day as top gainers, up between 1.3 to 1.8 per cent.

SI Reporter New Delhi
Photo: Kamlesh Pednekar
Photo: Kamlesh Pednekar

3 min read Last Updated : Oct 23 2019 | 3:58 PM IST

3:40 PM

Sectoral trends at NSE at close

3:40 PM

Top gainers and losers on S&P BSE Sensex at close

3:39 PM

Closing Bell

The benchmark S&P BSE Sensex settled 95 points, or 0.24 per cent, higher at 39,059 level. 10 of the 30 shares listed on the index ended the day in the red.

On NSE, the broader Nifty50 index closed at 11,604-mark, up 16 points or 0.14 per cent. 

3:30 PM

NEWS ALERT | Sadhbhav Infra signs definitive agreements with Indinfravit to sell 100% stake in 9 operational projects: BSE filing

-- Company has signed definitive agreements with Indinfravit on 1 July, 2019 to sell 100% stake in nine operational projects for an enterprise value of INR 66.1 bn (including equity value of INR 25.5 bn). Sales consideration of INR 25.5 bn shall split into units (10%  units of Indinfravit) and ~ 19 bn in cash.

-- Additional upsides from car revenues from ARRIL, extension of concession period for AJTL andclaims from the transaction assets shall flow to SIPL.
 

3:26 PM

NEWS ALERT | CDPQ in talks to raise stake in Piramal Ent: sources to CNBC TV18

-- Piramal Ent likely to raise $750 million

-- Canadian fund CDPQ could invest funds via Preferential issue

-- Piramal Ent's promoters may participate via Rights issue to retain holding

3:17 PM

Earnings Alert | Indian Bank Q2 result

-- Net profit at Rs 358.6 crore

-- GNPA ratio at 7.2% vs 7.33% QoQ

-- NNPA ratio at 3.54% vs 3.84% QoQ

-- NII at Rs 1,863 crore

3:11 PM

Dr Reddy's Laboratories recalls anti-ulcer drug ranitidine from US market

Dr Reddy's Laboratories Limited on Wednesday confirmed that it had initiated a voluntary nationwide recall of several lots of its ranitidine from the US market over confirmed contamination with N-Nitrosodimethylamine(MDMA) beyoond levels established by the US Food and Drug Administration (US FDA). READ MORE

3:00 PM

NEWS ALERT | Cabinet approves revival plan for MTNL & BSNL: CNBC TV18

3:00 PM

NEWS ALERT | MTNL, BSNL revival plan to include 4G spectrum, support for voluntary retirement schemes: CNBC TV18 via agencies

2:58 PM

Affle India soars 17% on filing 14 tech patents in Singapore, US

The stock, which was trading at its highest level since its listing on August 8, 2019, has appreciated by 91 per cent as against the issue price of Rs 745 per share.
 
“The company has filed 4 new patent applications in Singapore in the areas of conversational marketing and vernacular and voice-based intelligence,” Affle (India) said in a regulatory filing on Tuesday after market hours.  READ MORE

2:42 PM

Yesterday once more: How the latest crisis is playing out at Infosys

For the second time in about as many years, the Indian icon synonymous with the country’s technological ascendancy is being forced to answer accusations of impropriety. In the most recent of a stream of grievances aired anonymously over past years, whistle-blowers accused Chief Executive Officer Salil Parekh of instigating employees to inflate profits, mis-represent the lucrativeness of deals, even of abusing travel privileges. In a memo reproduced in local newspapers, Parekh’s accusers offered emails and recordings to back up their claims. READ MORE

2:28 PM

ALERT :: ICICI Securities Q2 PAT up 1% at Rs 135.12 crore

ICICI Securities has reported a one per cent rise in profit after tax (PAT) at Rs 135.12 crore for the September quarter. The company had posted a PAT of Rs 134.22 crore in July-September quarter of 2018-19, ICICI Securities said in a regulatory filing. The company. which is a part of the ICICI Group, posted a revenue of Rs 418.22 crore for the second quarter of 2019-20 as against Rs 458.10 crore in the year-ago quarter, down 9 per cent. The revenue fell mainly due to decline in retail broking revenues and regulatory changes in mutual funds distribution business.

(Source: PTI)

2:23 PM

PSU banks gained ground in trade today

2:22 PM

HDFC Securities on ICICI Pru Life

We like IPRU’s re-engineered business model which is focused on a more diversified product mix along with an increased protection share. We expect VNB to grow at FY19-22E CAGR of 17.5%. Lower than expected growth and lower protection share remain key risks. We rate IPRU a NEUTRAL with an unchanged target price of Rs 445 (Sep-20E EV + 19.2x Sep-21E VNB).

2:21 PM

Motilal Oswal on Oberoi Realty

2QFY20 was operationally weak on account of the subdued economic environment; however, OBER’s new launch pipeline in 2HFY20 provides comfort. We have cut our sales volume estimate for FY20/FY21E by 25%/16% to 1.2msf/1.6msf due to delayed launch of Exquisite III and the Thane project, which impacts our NAV calculation. However, anticipated tax benefit offsets the downside and we arrive at a TP of INR630. Maintain Buy.

Topics :MarketsMARKET WRAP

First Published: Oct 23 2019 | 7:07 AM IST